Alys Pharmaceuticals

An Innovation Leader in Immuno-Dermatology

immuno-dermatologydermatologybiotech/medtech

Founded2024

Employees8

LocationBoston, MA

Business modelB2B/B2C hybrid (focus on research collaborations and pipeline development with potential partnerships/licensing)

About

Launched in February 2024, Alys Pharmaceuticals is an innovation leader in immuno-dermatology, co-founded by Medixci and world-leading dermatology and scientific experts. Originating from the aggregation of six asset-centric Medixci compannies, Alys boasts a robust pipeline of innovative programs and platforms targeting multiple dermatological indications. With a vision to transform the treatment paradigm for several dermatology indications of significant prevalence and major unmet medical need, Alys aspires to redefine the landscape of dermatological treatments. Alys combines the assets and platforms of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics, and has a number of strategic collaborations with leading research institutions.

Product

Value proposition: R&D-driven immuno-dermatology company developing multi-platform therapies to redefine treatment landscapes for dermatologic conditions.

Founders

Thibaud Portal — Co-founder and COO
John Harris — Co-founder, Investor, and Chief Scientific Advisor
Brian Kim — Co-founder
Lars French — Co-founder
Craig Mello — Co-founder
Eric Deutsch — Co-founder
Mark Prausnitz — Co-founder
Francesco De Rubertis — Co-founder and Chairman of the Board
Michèle Ollier — Co-founder

Products

ALY-301 (mast cell selective c-Kit inhibitor)pipeline programs (multi-platform technologies)

Key features

Phase 1/1b first-in-class mast cell targeted therapymulti-platform R&D pipelineimmuno-dermatology focusearly-stage clinical developmentco-founders with dermatology and scientific expertise

Technologies

mast cell targeted inhibitorsc-Kit inhibitionmulti-platform biotechnologyimmunology/dermatology platforms

Target conditions

Chronic UrticariaCold UrticariaChronic Inducible Urticaria (CIndU)dermatologic conditions

Care settings

research laboratoriesclinical trialshospital/academic settings

News

With first drug now in the clinic, Alys eyes megaround for rest of pipeline · 2025-02-05T16:14:41.000Z
Clinical trial participant receives first dose of UMass Chan-developed treatment for alopecia areata by Alys Pharmaceuticals · 2025-05-09T14:08:02.000Z
Alys Pharmaceuticals receives IND clearance for Phase 2a trial of first genetic medicine program in dermatology – Alys Pharmaceuticals · 2025-02-04T08:30:09.000Z
Alys Pharmaceuticals doses first subject in Phase 1/1b trial of ALY-301, a first-in-class mast cell selective c-Kit inhibitor for Chronic Urticaria – Alys Pharmaceuticals · 2025-10-30T08:30:14.000Z
First-in-class mechanisms for the next wave of dermatology innovation - Drug Discovery World (DDW) · 2025-10-03T10:12:04.000Z
Alys Pharmaceuticals Announces Dosing of First Patient in Phase IIa Trial of ALY-101 for Alopecia Areata · 2025-03-27T08:30:00.000Z

Browse similar startups

Related startups

Assisted Living Navigation — Beverly, MA
Autus Valve Technologies, Inc. — Boston, MA
Baystate Noble Hospital Corporation — Westfield, MA
Bluebird Kids Health — Boston, MA
CarePassport — Newton, MA
CaviSense — Allston, MA
Associated Dermatology & Skin Cancer Clinic — Helena, MT
Derm to Door — mclean, VA
DERMATOLOGY AND SKIN CANCER SPECIALISTS, PSC — Owensboro, KY
Fine Skin Dermatology — Orland Park, IL
Mind The Skin Inc. — Houston, TX
MyMonitor.Ai — Philadelphia, PA

Profile updated Jul 29, 2026. Sources: alyspharma.com